University of California Irvine Alpha Stem Cell Clinic
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goyal, Namita
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
EPISOD1, NCT06100276: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting
1/2
20
US
AMT-162
UniQure Biopharma B.V.
Amyotrophic Lateral Sclerosis
09/26
03/31
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Zhou, Robert
No trials found

Download Options